YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
HKEX:1558.HK
8.19 (HKD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 6,294.585 | 3,744.952 | 913.788 | 2,348.113 | 6,224.024 | 2,510.476 | 1,601.567 | 941.504 | 692.91 | 440.904 | 316.429 |
| Cost of Revenue
| 1,308.821 | 898.878 | 430.089 | 351.547 | 921.822 | 398.809 | 280.416 | 214.234 | 178.334 | 119.829 | 115.968 |
| Gross Profit
| 4,985.764 | 2,846.074 | 483.699 | 1,996.566 | 5,302.202 | 2,111.667 | 1,321.151 | 727.27 | 514.576 | 321.075 | 200.461 |
| Gross Profit Ratio
| 0.792 | 0.76 | 0.529 | 0.85 | 0.852 | 0.841 | 0.825 | 0.772 | 0.743 | 0.728 | 0.634 |
| Reseach & Development Expenses
| 192.287 | 129.614 | 136.653 | 119.428 | 162.619 | 224.103 | 96.915 | 64.236 | 52.303 | 73.584 | 81.275 |
| General & Administrative Expenses
| 385.702 | 338.452 | 358.402 | 318.068 | 503.413 | 384.385 | 192.985 | 132.711 | 118.239 | 107.86 | 110.121 |
| Selling & Marketing Expenses
| 1,547.15 | 1,216.59 | 521.667 | 1,153.884 | 2,361.049 | 653.65 | 372.09 | 180.887 | 77.287 | 60.115 | 30.599 |
| SG&A
| 1,932.852 | 1,551.047 | 883.245 | 1,467.561 | 2,869.196 | 1,038.035 | 565.075 | 313.598 | 197.458 | 170.427 | 140.72 |
| Other Expenses
| -1.005 | 0.172 | 0.06 | 255.197 | -4.608 | 5.509 | -0.337 | -2 | -1.328 | -0.027 | 0 |
| Operating Expenses
| 2,108.166 | 2,531.745 | 918.422 | 766.913 | 2,864.684 | 1,022.526 | 583.404 | 275.075 | 177.143 | 136.931 | 103.893 |
| Operating Income
| 2,354.198 | 322.721 | -458.106 | 833.694 | 2,529.515 | 1,083.435 | 762.48 | 419.566 | 329.419 | 184.149 | 96.753 |
| Operating Income Ratio
| 0.374 | 0.086 | -0.501 | 0.355 | 0.406 | 0.432 | 0.476 | 0.446 | 0.475 | 0.418 | 0.306 |
| Total Other Income Expenses Net
| 9,307.387 | -283.299 | -209.078 | 176.74 | -260.462 | 18.889 | -14.285 | 33.5 | -14.713 | -21.034 | -26.573 |
| Income Before Tax
| 2,126.771 | 39.422 | -667.184 | 1,010.434 | 2,269.053 | 1,102.324 | 748.195 | 453.066 | 314.706 | 163.115 | 70.18 |
| Income Before Tax Ratio
| 0.338 | 0.011 | -0.73 | 0.43 | 0.365 | 0.439 | 0.467 | 0.481 | 0.454 | 0.37 | 0.222 |
| Income Tax Expense
| 270.945 | 9.817 | 79.46 | 173.023 | 361.868 | 201.106 | 121.838 | 72.469 | 48.956 | 27.772 | 12.38 |
| Net Income
| 1,992.624 | 76.603 | -587.649 | 839.455 | 1,918.709 | 942.536 | 647.101 | 380.597 | 265.75 | 135.343 | 57.8 |
| Net Income Ratio
| 0.317 | 0.02 | -0.643 | 0.358 | 0.308 | 0.375 | 0.404 | 0.404 | 0.384 | 0.307 | 0.183 |
| EPS
| 2.26 | 0.087 | -0.67 | 0.95 | 2.16 | 1.04 | 0.72 | 0.42 | 0.4 | 0.23 | 0 |
| EPS Diluted
| 2.26 | 0.087 | -0.67 | 0.53 | 2.07 | 1.04 | 0.72 | 0.42 | 0.4 | 0.23 | 0 |
| EBITDA
| 3,295.851 | 691.483 | -206.554 | 950.235 | 2,611.348 | 1,144.523 | 806.275 | 447.015 | 355.166 | 216.094 | 126.321 |
| EBITDA Ratio
| 0.524 | 0.185 | -0.226 | 0.405 | 0.42 | 0.456 | 0.503 | 0.475 | 0.513 | 0.49 | 0.399 |